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Key messages
What is already known about this subject?
 ► Intermetatarsal bursitis (IMB) is frequent in patients 
with rheumatoid arthritis (rA), but there are large 
discrepancies in the described prevalence and the 
most frequent localisations.
What does this study add?
 ► We found that one in five patients with established 
rA had IMB, and that most of the bursitis were lo-
cated in the spaces between metatarsophalangeal 
(Mtp) joint 2 and 3 as well as between Mtp 3 and 4. 
the presence of IMB was not associated with the to-
tal ultrasound scores of a high number of joints/ten-
dons, but with the ultrasound scores of inflammation 
in the Mtp joints. In addition, presence of IMB was 
associated with presence of anti-cyclic citrullinated 
peptide and rheumatoid factor antibodies.
How might this impact on clinical practice?
 ► Clinicians should explore for IMB as a cause of fore-
foot pain especially in patients with seropositive 
rheumatoid arthritis.
InTroduCTIon
Ultrasound is sensitive for detection of 
inflammatory changes in patients with rheu-
matoid arthritis (RA).1 Intermetatarsal 
bursitis (IMB) is located on the dorsal side of 
the deep intermetatarsal ligament and may 
easily be detected by use of longitudinal and 
transverse dorsal scans between the meta-
tarsophalangeal (MTP) joints.2 In a longitu-
dinal scan, they are relatively large and have 
usually a round shape, caused by hypoechoic 
synovitis and they may contain fluid. They 
are often power Doppler (PD) positive. In 
the transverse plane, an IMB is detected as a 
hypoechoic structure between the metatarsal 
heads where the upper border is rounded. 
There are few studies on IMB,3–6 and the 
objective of this study was to explore the prev-
alence of IMB and its associations with subjec-
tive, clinical and laboratory assessments in 
established RA patients.
MeTHods
This post hoc analysis of 209 patients with RA 
(mean (SD) age 53 (13) years, disease dura-
tion 10 (9) years, 81% women, 79% anti-cyclic 
citrullinted peptide (anti-CCP) positive, 69% 
rheumatoid factor (RF) positive) initiating 
biological disease-modifying antirheumatic 
drugs (bDMARDs)7 included assessment 
of patient’s global disease activity VAS, clin-
ical examination (assessor’s disease activity 
VAS, tender and swollen joint counts (of 28) 
performed by a study nurse, with additional 
MTP 1-5 assessed combined as one joint 
bilaterally for tenderness) and laboratory 
variables (Erythrocyte Sedimentation Rate 
(ESR), C-Reactive Protein (CRP), anti-CCP 
and RF). Composite clinical scores (Disease 
Activity Score of 28 joints (DAS28,ESR), 
Clinical Disease Activity Index (CDAI) and 
Simplified Disease Activity Index (SDAI) 
were calculated. The presence of patient-re-
ported joint pain (PRJP) was scored 0–3 at 
joint level for pain the last 24 hours by use of 
a manikin (including bilateral wrist, MCP1–5, 
PIP2–3, elbow, knee, ankle, MTP 1–5), and 
the same joints were examined by ultrasound. 
A semi-quantitative score (0–3) using grey 
scale (GS) and PD were performed by one 
rheumatologist with high intra-reader reli-
ability8 by use of Siemens Acuson Antares, 
excellence version, 5–13 MHz probe and in 
accordance with the Norwegian ultrasound 
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Figure 1 RA patient with intermetatarsal bursitis between 
MTP2 and MTP3. (A) Longitudinal, dorsal scan of normal 
MTP2. (B) Longitudinal, dorsal scan of normal MTP3. (C) 
Longitudinal dorsal grey scale scan of intermetatarsal bursitis 
between MTP2 and MTP3. (D) Similar to (C), with power 
Doppler. (E) Photo of RA patient with intermetatarsal bursitis 
between MTP2 and MTP3. RA, rheumatoid arthritis; MTP, 
metatarsal phalangeal joint.
atlas.8 In addition, both feet were at each examination 
assessed by dorsal longitudinal scan (and transverse when 
indicated), of all spaces between the MTP joints for IMB. 
The presence of MTP synovitis (defined as GS score ≥2) 
was explored for the two MTP joints neighbouring the 
IMB. Baseline sum scores of GS, PD and PRJP of all joints 
as well as of only MTP 1–5 bilaterally were calculated. 
Associations were explored by use of Mann-Whitney test, 
ORs and binary logistic regression analysis.
resulTs
Forty-three patients (20.6%) had a total of 69 IMB, either 
unilaterally or bilaterally (27.9% right side, 37.2% left 
side and 30.2% bilaterally, while in 4.7% there was no 
description of side). The patients had up to 4 IMB (n=1 
in 65.1%, n=2 in 18.6%, n=3 in 7.0% and n=4 in 9.3%). 
Figure 1 shows the typical clinical and longitudinal GS/
PD ultrasound scanning of IMB. IMB was found in the 
following intermetatarsal spaces: MTP 1–2; 4.3%, MTP 
2–3; 33.3%, MTP 3–4; 56.5% and MTP 4–5; 5.8%. When 
IMB was found, there was no synovitis in neighbouring 
MTPs in 33.3%, synovitis in one of the MTPs in 29.0% 
and synovitis in both MTPs in 37.7%. However, if synovitis 
was present, it was mainly moderate (mostly GS score of 
2 (in 95.7%)). There were no differences in the presence 
of anti-CCP/RF in patients with vs without synovitis in the 
neighbouring MTPs.
Presence of IMB was not associated with baseline 
total sum scores of GS, PD or PRJP, or with the clinical 
or composite scores assessments. However, patients with 
IMB had significantly higher MTP 1–5 sum scores of GS 
and PD (p=0.05 and p=0.002, respectively), but no differ-
ence in sum score PRJP or tenderness of MTPs. Logistic 
regression analysis with either anti-CCP or RF positivity 
as the dependent variable showed that presence of IMB 
significantly explained seropositivity, while this was not 
found for GS and PD sum scores of MTP 1–5 as inde-
pendent variables. In addition, IMB was associated with 
anti-CCP (OR (95% CI) 4.1 (1.2 to 14.0)) and RF (3.7 
(1.4 to 10.1)), with 93% of patients with IMB being 
anti-CCP positive and 87% RF positive.
dIsCussIon
The present frequency of IMB was as described in the 
study by Iagnocco et al.3 However, we found much lower 
percentage of patients with IMB than Bowen et al5 who 
described IMB in 90.8% of RA patients. In addition, in 
contrast to our study, Bowen et al found most of the IMB 
located in the MTP 4–5 space and least in the MTP 2–3 
space. In the study by Bowen et al, only plantar longitu-
dinal and transverse scans were used, while we assessed 
the IMB by use of dorsal longitudinal and transverse scan-
ning. A recent retrospective study including conventional 
MRI and ultrasound used dorsal scans for the ultrasound 
examination of IMB.6 However, MRI found the IMB to 
be big enough to be easily detectable by both dorsal and 
plantar scanning.
All patients in the present study were treated with 
bDMARDs, and this could have reduced the presence 
of IMB. However, a previous study has addressed the 
change of forefoot bursal hypertrophy after 12 weeks 
of bDMARD treatment.9 They found no significant 
change, only a trend towards reduction. Thus, it seems 
that despite effective anti-inflammatory treatment, these 
bursae may take time to normalise.
We found no associations between the presence of 
IMB and clinical or patient-reported outcomes. This 
is supported by a previous study exploring the long-
term associations between changes in forefoot bursae 
(including both IMB and plantar bursae) and changes in 
DAS28 or ESR,10 where no significant associations were 
found over 3 years. On the other hand, presence of fore-
foot bursae was associated with patient-reported foot-re-
lated disability scores. This is supported by the present 
findings, where ultrasound sum scores of the MTP joints 
were higher in patients having IMB.
ConClusIon
Our study shows that IMB is a frequent finding in patients 
with established RA and primarily in the MTP 2–3 and 
MTP 3–4 spaces. IMB was associated with higher levels 
of ultrasound synovitis in MTPs as well as with presence 
of anti-CCP and RF. Thus, ultrasound examination of 
forefeet should also focus on this pathology which may 
be typical for seropositive RA and indicate more severe 
disease of the feet.
Acknowledgements We want to thank Anne Katrine Kongtorp and Britt Birketvedt 
who were study nurses and performed important assessments including the 
clinical examinations in the study.
Contributors hBh has made a substantial contributions to the conception and 
design of the work; the acquisition of data, all the analysis, interpretation of 
data for the work; and drafted the manuscript as well as revising it critically for 
important intellectual content; and given a final approval of the version to be 
published; and agree to be accountable for all aspects of the work in ensuring 
that questions related to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. tKK and Lt have given substantial 
contributions to the design of the manuscript as well as the interpretation of 
Protected by copyright.
 o
n
 M
ay 10, 2020 at Kobenhavns Universitets Bibliotek.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2019-001076 on 17 O
ctober 2019. Downloaded from
 
3hammer hB, et al. RMD Open 2019;5:e001076. doi:10.1136/rmdopen-2019-001076
Rheumatoid arthritis
data for the work; and revised the manuscript critically for important intellectual 
content; and given a final approval of the version to be published; and agree to be 
accountable for all aspects of the work in ensuring that questions related to the 
accuracy or integrity of any part of the work are appropriately investigated and 
resolved.
Funding this work was supported by AbbVie, pfizer and roche in form of study 
grants to the Department of rheumatology, Diakonhjemmet hospital, oslo/ hilde 
Berner hammer.
Competing interests None declared.
Patient consent for publication Not required.
ethics approval the study was approved by the Norwegian regional Committee 
for Medical and health research ethics South east (reference number 2009/1254) 
and the patients gave their written informed consent according to the Declaration 
of helsinki.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement Data are available upon request.
open access this is an open access article distributed in accordance with 
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this work 
non-commercially, and license their derivative works on different terms, provided 
the original work is properly cited, appropriate credit is given, any changes made 
indicated, and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/.
orCId id
hilde Berner hammer http:// orcid. org/ 0000- 0001- 7317- 8991
RefeRences
 1 Tan YK, Ostergaard M, Bird P, et al. Ultrasound versus high field 
magnetic resonance imaging in rheumatoid arthritis. Clin Exp 
Rheumatol 2014;32:S99–105.
 2 Bianchi S. Practical us of the forefoot. J Ultrasound 2014;17:151–64.
 3 Iagnocco A, Coari G, Palombi G, et al. Sonography in the study of 
metatarsalgia. J Rheumatol 2001;28:1338–40.
 4 Endo Y, Koga T, Eguchi M, et al. Utility of power Doppler 
ultrasonography for detecting forefoot bursae in early rheumatoid 
arthritis. Medicine 2018;97:e13295.
 5 Bowen CJ, Hooper L, Culliford D, et al. Assessment of the natural 
history of forefoot bursae using ultrasonography in patients with 
rheumatoid arthritis: a twelve-month investigation. Arthritis Care Res 
2010;62:1756–62.
 6 Albtoush OM, Xenitidis T, Horger M. Intermetatarsal bursitis as first 
disease manifestation in different rheumatological disorders and 
related MR-imaging findings. Rheumatol Int 2019;25. doi:10.1007/
s00296-019-04381-x. [Epub ahead of print: 18 Jul 2019].
 7 Hammer HB, Uhlig T, Kvien TK, et al. Pain catastrophizing, 
subjective outcomes, and inflammatory assessments including 
ultrasound: results from a longitudinal study of rheumatoid arthritis 
patients. Arthritis Care Res 2018;70:703–12.
 8 Hammer HB, Bolton-King P, Bakkeheim V, et al. Examination of intra 
and interrater reliability with a new ultrasonographic reference atlas 
for scoring of synovitis in patients with rheumatoid arthritis. Ann 
Rheum Dis 2011;70:1995–8.
 9 Bowen CJ, Edwards CJ, Hooper L, et al. Improvement in symptoms 
and signs in the forefoot of patients with rheumatoid arthritis treated 
with anti-TNF therapy. J Foot Ankle Res 2010;3:10.
 10 Hooper L, Bowen CJ, Gates L, et al. Prognostic indicators of foot-
related disability in patients with rheumatoid arthritis: results of a 
prospective three-year study. Arthritis Care Res 2012;64:1116–24.
Protected by copyright.
 o
n
 M
ay 10, 2020 at Kobenhavns Universitets Bibliotek.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2019-001076 on 17 O
ctober 2019. Downloaded from
 
